Covance Business Unit Names New Leaders
Following the recent announcement that Dr. Paul Kirchgraber would assume the role of CEO of Covance, two key leadership appointments will also become effective November 1.
Jon Divincenzo.,高级VP,是临床试验检测解决方案的传入负责人,监督Covance Central实验室服务(CLS),化学解决方案(包括生物分析和化学制造和控制)和全球标本解决方案。Patrick Hastings,VP已被命名为CLS组织的传入负责人。
DiVincenzo joined Covance in 2017, bringing more than 30 years’ experience in life science and analytical instrumentation, focused on driving international growth, executing strategic objectives and building high-performance teams, particularly in biotechnology, pharmaceutical and clinical institutions. Most recently, served as SVP and head of Covance’s Chemistry Solutions organization. Prior to joining Covance, DiVincenzo was CEO of a Boston-based Contract Manufacturing Organization (CMO), supplying the DNA sequencing market. He is a graduate of Northeastern University in Boston where he earned a Bachelor’s Degree in Mechanical Engineering and holds certificates in Product Management and Marketing from the University of Wisconsin in Madison.
Hastings joined Covance in 2016. Most recently, he served as VP, Global Operations and Client Delivery for CLS, providing him with substantial insight about both the business and our exceptional people. Prior to Covance, Hastings led the global Clinical Trials production and supply chain operations for Eli Lilly & Company supporting more than 13,000 clinical sites with an extensive internal and external manufacturing network. In addition, Hastings served as Chief Operating Officer for a medical device firm, where he successfully led the launch of more than 25 innovative products supporting the oncology laboratory testing industry, and drove several transformational initiatives to significantly improve revenue and margin. He earned his Master’s Degree in Engineering from Rutgers University, a Bachelor of Science degree from Michigan State University, and Executive Management certifications from the Kellogg School of Management at Northwestern University and the University of Notre Dame.
“我亲自与乔恩和帕特里克一起工作了几年,并知道他们将继续加强董事会文化和工作的方式,”基尔科勒说。“而且,我有信心的是,乔恩和帕特里克准备基于他们以前的成功记录前进的新机会。”
关于Labcorp.
Covance is the drug development business of LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenue of more than $11 billion in 2018. To learn more about LabCorp, visitwww.labcorp.com., and to learn more about Covance Drug Development, visitwww.wfliji.com.